At ErVaccine Technologies S.A., a French biotech company incorporated in October 2019, we develop next-generation cancer vaccines and T-cell therapies. We pursue an innovative approach for new immunotherapies by exploiting the role of human endogenous retroviruses (HERVs). En savoir plus
